UPDATE | November 28, 2022

Investing in the future of mRNA Manufacturing

  • MAIL

WHITEPAPER - Investing in the future of mRNA Manufacturing
 

A novel technology, mRNA has the potential to broaden treatment options for many diseases and disorders. As mRNA becomes a major focus of drug development, it is necessary to partner with a one-stop CDMO to eliminate the increased risk associated with multiple tech transfers, as well as the added time and cost. In this whitepaper, Esther Yoo, Head of Development Sales, offers insights on how Samsung has been exploring the possibilities of mRNA since before the pandemic and is now leveraging this expertise. 

WHITEPAPER - Investing in the future of mRNA Manufacturing
 

A novel technology, mRNA has the potential to broaden treatment options for many diseases and disorders. As mRNA becomes a major focus of drug development, it is necessary to partner with a one-stop CDMO to eliminate the increased risk associated with multiple tech transfers, as well as the added time and cost. In this whitepaper, Esther Yoo, Head of Development Sales, offers insights on how Samsung has been exploring the possibilities of mRNA since before the pandemic and is now leveraging this expertise. 

  • CDO
  • CGMP
  • ADC
  • Bio Campus
  • IR
  • CMO

Share article

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Interests
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy required